So far, all controlled clinical trials for the treatment of systemic sclerosis-associated ILD have used cyclophosphamide as at least the first phase of treatment. The evidence on which choices of treatment for other forms of CTD-ILD can be based is largely restricted to small series and retrospective data suggesting the potential role of several immunosuppressive interventions.